A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.
about
Mechanisms of action of glucagon-like peptide 1 in the pancreasReport from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell ReplacementPPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyPathophysiology of Non Alcoholic Fatty Liver DiseaseScientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.Deletion of PKCepsilon selectively enhances the amplifying pathways of glucose-stimulated insulin secretion via increased lipolysis in mouse beta-cellsChronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin ResistanceLow sensitivity of the metabolic syndrome to identify adolescents with impaired glucose tolerance: an analysis of NHANES 1999-2010.PGC-1alpha inhibits oleic acid induced proliferation and migration of rat vascular smooth muscle cells.Progression of diet-induced diabetes in C57BL6J mice involves functional dissociation of Ca2(+) channels from secretory vesicles.Glucolipotoxicity of the pancreatic beta cell.Lack of lipotoxicity effect on {beta}-cell dysfunction in ketosis-prone type 2 diabetes.Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohortThe relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose toleranceOral antihyperglycemic therapy for type 2 diabetes mellitus.Lipid-induced insulin resistance is associated with increased monocyte expression of scavenger receptor CD36 and internalization of oxidized LDL.Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjectsJunB protects β-cells from lipotoxicity via the XBP1-AKT pathway.Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Reduced first-phase insulin secretion increases postprandial lipidemia in subjects with impaired glucose toleranceFSP27 promotes lipid droplet clustering and then fusion to regulate triglyceride accumulation.Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass.Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.Palmitate induces mRNA translation and increases ER protein load in islet β-cells via activation of the mammalian target of rapamycin pathwayAdjusting glucose-stimulated insulin secretion for adipose insulin resistance: an index of β-cell function in obese adults.Integrated lipidomics and transcriptomic analysis of peripheral blood reveals significantly enriched pathways in type 2 diabetes mellitus.Relationships between mitochondrial function and metabolic flexibility in type 2 diabetes mellitus.Identification of ATP synthase as a lipid peroxide protein adduct in pancreatic islets from humans with and without type 2 diabetes mellitus.Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humansYi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats.Chronic glucolipotoxic conditions in pancreatic islets impair insulin secretion due to dysregulated calcium dynamics, glucose responsiveness and mitochondrial activity.The class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate.Small-molecule inhibition of inflammatory β-cell death.Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease.Higher acute insulin response to glucose may determine greater free fatty acid clearance in African-American women.Obese first-degree relatives of patients with type 2 diabetes with elevated triglyceride levels exhibit increased β-cell functionMetabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trialDapagliflozin lowers plasma glucose concentration and improves β-cell functionExogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids.
P2860
Q24683764-B0336EF9-B43F-4B98-BA90-8C008A2F3E78Q26769878-69328E56-0549-498C-9732-C12D2B44815DQ27024799-7B1C89B0-3E29-4668-8BE1-FE39506CAD33Q28070011-5C792154-6103-4A9F-A139-B2CB626DD648Q28390200-BF7AAAF7-C239-4FA1-865C-B634DCB23505Q28506519-B8FED0B0-1F86-4B29-8CC6-6B87729D24D9Q28555023-6254DBE0-1E30-435B-BE26-D9681AC394CAQ30413659-5D36727D-A924-4F04-A1D3-9B2EF3C27148Q33305208-5ECC0854-9168-4A77-8C1C-74E96C5B9FF5Q33530805-4B8145B2-4C7E-4AD9-B960-12EED77E3F08Q33665283-3CC14026-E18C-4C62-B480-392BD0676DF5Q33683768-921E0FE9-A82A-4F6E-BC3D-563EEC51C21EQ33691736-BBC7C4B8-A676-4DBA-A6FA-91895103F454Q33705046-7885C246-D7B7-4FDA-BD63-BE457E13D46BQ33713451-7BFDC490-8F53-4035-B74E-2AF61A240A51Q33719103-ADFA0C6D-6AA0-40BC-ABE4-225A53B71762Q33723943-CBDB8DED-E51E-43D0-82D6-993677B06774Q33858456-252C834A-6B9E-41FC-8D0D-DA174E144737Q33880303-BD9BB917-F814-40DA-B844-BFA04630FA1EQ33883131-C93869FE-475B-47B7-B116-9B405A21C8D9Q34110186-FD6165F5-A006-4B78-AA32-BBD603F141C4Q34139048-BD38F15E-7C1B-4170-BF28-DDE034492EF8Q34163947-523BA6BA-24E9-47FC-B475-5D300607F8CBQ34191173-3CA78527-714C-4F2A-B0B5-3939B0FD2DD1Q34227880-B3DBA769-4DCB-4380-88CE-9CF123346DECQ34392359-BB3F30A5-FA1B-4769-BBB8-70F1B40CDB2FQ34570007-1ED62522-DF0D-479E-9EEB-A6A6149E75CEQ34589466-82BE7615-0AE1-4BE8-B27F-85684C2685C7Q34609574-A459D6EC-0767-41CD-AD1F-73646964405CQ34615491-F966BBF5-7910-4E72-AA17-186A20A012EEQ34671018-85D9D45E-6F11-48EE-8789-42192ACE0A38Q34787903-EC5CE369-DE62-4550-B0D2-9606D94806F2Q34956310-49D4973E-6062-43F3-9544-A48E865AEA8CQ34978002-4BC3BB6C-21CC-44B5-A496-E9351B6E6FFBQ35126355-853ABBC6-1A77-462F-A7B1-B9C5C6C2ABD7Q35137180-9AB4CD13-EDE1-4BCF-B48A-02E935FBB6F7Q35180903-C1B4E3CC-7493-4C15-9AA9-500400D68B9DQ35507040-063B1C67-E1B4-4452-8C1E-4D993A1E13A3Q35578244-0EB00178-B4B7-440A-ADD0-C518D4E79B14Q35597914-F3581409-E909-4F64-B720-D2E8F1DDA2B1
P2860
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A sustained increase in plasma ...... ed to develop type 2 diabetes.
@en
A sustained increase in plasma ...... ed to develop type 2 diabetes.
@nl
type
label
A sustained increase in plasma ...... ed to develop type 2 diabetes.
@en
A sustained increase in plasma ...... ed to develop type 2 diabetes.
@nl
prefLabel
A sustained increase in plasma ...... ed to develop type 2 diabetes.
@en
A sustained increase in plasma ...... ed to develop type 2 diabetes.
@nl
P2093
P921
P1433
P1476
A sustained increase in plasma ...... ed to develop type 2 diabetes.
@en
P2093
Kenneth Cusi
Lawrence Mandarino
Mandeep Bajaj
Rachele Berria
Renata Belfort
Sangeeta Kashyap
Thongchai Pratipanawatr
Wilailak Pratipanawatr
P304
P356
10.2337/DIABETES.52.10.2461
P407
P577
2003-10-01T00:00:00Z